RxDoctor Payments DataLook up a doctor →

Jennifer Caicedo, MD

Allergy & Immunology · Charlotte, NCNPI 1043490113

Payments from drug & device makers

$174,334in general payments, 2019–2025

Across 789 payments — averaging $220.96 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Takeda Pharmaceuticals U.S.A., Inc.$64K
  • AstraZeneca$34K
  • Bristol Myers Squibb$25K
  • GSK$14K
  • Sanofi US Services Inc.$11K
  • Genentech, Inc.$8K
  • plus $19K from 35 others

What the payments were for

  • Consulting fees$1,8294%
  • Speaking & faculty fees$29,60060%
  • Travel & lodging$8172%
  • Food & beverage$17,26135%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$174,334 in reported general payments places this provider in the 85th percentile of 140 allergy & immunology providers in North Carolina.

See all allergy & immunology providers in North Carolina

Medicare billing

Part B allowed, 2024
$116,017
Medicare patients
136
Services billed
7,123

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Dupixent PenDupilumab14$100,100
XolairOmalizumab30$64,399
Breztri AerosphereBudesonide/Glycopyr/Formoterol17$17,919
SymbicortBudesonide/Formoterol Fumarate14$4,493
Epinephrine14$2,839
Levocetirizine Dihydrochloride128$2,140
Budesonide-Formoterol FumarateBudesonide/Formoterol Fumarate11$1,882
Azelastine Hcl54$1,717
Desloratadine21$556
Carbinoxamine Maleate19$485
Ipratropium Bromide28$457
Albuterol Sulfate HfaAlbuterol Sulfate19$442
Fluticasone Propionate21$430
Montelukast Sodium20$245
Mometasone Furoate12$215

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Genentech, Inc.Xolair$7,696$64,39930 claims
AstraZenecaBreztri Aerosphere, Symbicort$33,972$22,41331 claims
Hikma Pharmaceuticals USAEpinephrine$88$2,83914 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 140 allergy & immunology providers in North Carolina.

Other allergy & immunology in Charlotte

See the full list for North Carolina

Where these figures come from

Is this you, or does something look wrong? →